Finall Exam:l NRl 568/l NR568l (NEWl
2026/l 2027l Update)l Advancedl
Pharmacologyl forl thel AGPCNPl Guidel |l
Questionsl &l Answersl |l Gradel A|l 100%l
Correctl (Verifiedl Solutions)-Chamberlain
QUESTION
firstl linel treatmentl forl migraine
Answer:
Serotoninl 1B/1Dl receptorl agonistsl (triptans)l arel first-linel medicationsl forl treatingl activel
migraines.
Thesel agentsl relievel painl byl constrictingl intracraniall bloodl vesselsl andl suppressingl
releasel ofl inflammatoryl neuropeptides.
QUESTION
Triptanl migrainel indication
Answer:
Triptansl arel indicatedl tol abortl anl activel migrainel episode.l Thesel medicationsl relievel
migrainel headachesl andl associatedl symptomsl ofl nausea,l neckl pain,l photophobia,l andl
phonophobia.
QUESTION
Sumatriptanl sidel effects
Answer:
,QUESTION
Sumatriptanl drugl interaction
Answer:
Sincel triptansl andl [ergots]l bothl causel vasoconstriction,l takingl theml concomitantlyl canl
causel excessivel orl prolongedl [vasospasm].l Triptansl shouldl notl bel usedl withinl [24l
hours]l ofl anl ergotl orl anotherl triptan.
[MAOIs]l canl suppressl thel hepaticl metabolisml ofl sumatriptan,l potentiallyl causingl
[toxicity]l andl makingl thisl combinationl contraindicated.
Usingl triptansl simultaneouslyl withl [SSRIsl orl SNRIs]l canl increasel thel riskl ofl [serotoninl
syndrome],l asl triptansl directlyl activatel [serotoninl receptors].
QUESTION
Sumatriptanl dosing
Answer:
Sumatriptanl orall dosingl rangesl froml 25mgl -l 100l mgl atl symptoml onsetl withl al repeatl
dosel inl twol hoursl forl al maximuml dosel ofl 200l mgl inl 24l hrs.
Sumatriptanl nasall sprayl isl dosedl asl 5l orl 20l mgl atl symptoml onsetl withl al repeatl dosel
inl twol hoursl withl al maximuml dosel ofl 40l mgl inl 24l hours.
Sumatriptanl vial subcutaneousl administrationl isl dosedl atl 6l mgl atl symptoml onsetl withl al
repeatl dosel inl onel hourl withl al maximuml dosel ofl 12l mgl inl 24l hours.
QUESTION
ergotaminel alkoloidl forl migraine
Answer:
2ndl linel treatmentl forl migraine
whenl clientsl arel notl responsivel tol triptans.l Theyl arel alsol usedl forl clusterl headaches.
QUESTION
ergotaminel moa
Answer:
,Thel primaryl mechanisml ofl actionl ofl ergotaminel inl thel treatmentl ofl migrainel isl notl
fullyl understood.l Ergotaminel canl alterl transmissionl atl serotonergic,l dopaminergic,l andl
alpha-adrenergicl junctions.l Currentl evidencel revealsl thatl antimigrainel effectsl couldl bel
relatedl tol agonistl activityl atl serotoninl receptors.l Inl craniall arteries,l ergotaminel actsl
directlyl tol promotel constrictionl andl reducel thel amplitudel ofl pulsations.
QUESTION
ergotaminel indication/use
Answer:
Ergotl alkaloidsl arel second-linel agentsl tol abortl activel migrainesl inl clientsl notl responsivel
tol triptans.
Usedl duringl activel migrainesl whenl clientsl arel unresponsivel tol first-linel treatment.
Canl leadl tol ergotism.
QUESTION
ergotl alkaloidl sidel effects
Answer:
QUESTION
ergotl alkaloidl blackl boxl warning
Answer:
canl causel intensel vasospasml andl subsequentl cerebrall orl peripherall ischemia.
QUESTION
ergotl alkaloidl dosing
Answer:
Sublinguall formulationsl arel administeredl asl onel tabletl (2l mg)l underl thel tonguel atl
migrainel onset.l Itl mayl bel repeatedl withl onel additionall tabletl atl 30-minutel intervalsl
twice.
, Ergotaminel andl caffeinel arel dosedl atl onel tol twol tabletsl (1mg/100l mg)l atl migrainel
onset.l Onel tabletl mayl bel repeatedl atl 30-minutel intervalsl fourl morel times.
Suppositoryl formulationsl (ergotaminel tartrate)l arel dosedl atl 2l mg/100l mg,l withl onel
suppositoryl PRl atl migrainel onsetl andl repeatedl inl onel hourl ifl needed.
Dihydroergotaminel intranasall sprayl isl dosedl atl onel sprayl (0.5l mg)l inl eachl nostrill atl
migrainel onset.l Itl mayl bel repeatedl inl 15l minutes.
QUESTION
ergotaminel teaching
Answer:
Clientsl shouldl bel counseledl onl thel riskl ofl ergotism,l symptomsl tol monitor,l andl thel
needl tol seekl medicall attentionl immediatelyl ifl warningl signsl orl symptomsl develop.
QUESTION
telll mel aboutl Serotoninl 1B/1Dl Receptorl Agonistsl (sumatriptanl [Imitrex])
Answer:
First-linel treatmentl forl activel migraines.
Directlyl stimulatesl serotoninl receptors.
Availablel inl injectable,l intranasal,l andl orall forms.l Canl causel coronaryl vasospasm.
Canl causel chestl symptomsl andl heavyl arms.
QUESTION
canl youl usel sumatriptanl orl ergotaminel inl pregnancy?
Answer:
Sumatriptanl wasl previouslyl classifiedl asl al Pregnancyl Riskl Categoryl Cl agent.l Itl shouldl
bel avoidedl inl pregnancyl unlessl necessary.
Ergotaminel wasl previouslyl classifiedl asl al Pregnancyl Riskl Categoryl Xl agent.l Itsl usel inl
pregnancyl isl contraindicatedl andl relatedl tol thel promotionl ofl uterinel contractions.
QUESTION
treatmentl forl mildl migraines
2026/l 2027l Update)l Advancedl
Pharmacologyl forl thel AGPCNPl Guidel |l
Questionsl &l Answersl |l Gradel A|l 100%l
Correctl (Verifiedl Solutions)-Chamberlain
QUESTION
firstl linel treatmentl forl migraine
Answer:
Serotoninl 1B/1Dl receptorl agonistsl (triptans)l arel first-linel medicationsl forl treatingl activel
migraines.
Thesel agentsl relievel painl byl constrictingl intracraniall bloodl vesselsl andl suppressingl
releasel ofl inflammatoryl neuropeptides.
QUESTION
Triptanl migrainel indication
Answer:
Triptansl arel indicatedl tol abortl anl activel migrainel episode.l Thesel medicationsl relievel
migrainel headachesl andl associatedl symptomsl ofl nausea,l neckl pain,l photophobia,l andl
phonophobia.
QUESTION
Sumatriptanl sidel effects
Answer:
,QUESTION
Sumatriptanl drugl interaction
Answer:
Sincel triptansl andl [ergots]l bothl causel vasoconstriction,l takingl theml concomitantlyl canl
causel excessivel orl prolongedl [vasospasm].l Triptansl shouldl notl bel usedl withinl [24l
hours]l ofl anl ergotl orl anotherl triptan.
[MAOIs]l canl suppressl thel hepaticl metabolisml ofl sumatriptan,l potentiallyl causingl
[toxicity]l andl makingl thisl combinationl contraindicated.
Usingl triptansl simultaneouslyl withl [SSRIsl orl SNRIs]l canl increasel thel riskl ofl [serotoninl
syndrome],l asl triptansl directlyl activatel [serotoninl receptors].
QUESTION
Sumatriptanl dosing
Answer:
Sumatriptanl orall dosingl rangesl froml 25mgl -l 100l mgl atl symptoml onsetl withl al repeatl
dosel inl twol hoursl forl al maximuml dosel ofl 200l mgl inl 24l hrs.
Sumatriptanl nasall sprayl isl dosedl asl 5l orl 20l mgl atl symptoml onsetl withl al repeatl dosel
inl twol hoursl withl al maximuml dosel ofl 40l mgl inl 24l hours.
Sumatriptanl vial subcutaneousl administrationl isl dosedl atl 6l mgl atl symptoml onsetl withl al
repeatl dosel inl onel hourl withl al maximuml dosel ofl 12l mgl inl 24l hours.
QUESTION
ergotaminel alkoloidl forl migraine
Answer:
2ndl linel treatmentl forl migraine
whenl clientsl arel notl responsivel tol triptans.l Theyl arel alsol usedl forl clusterl headaches.
QUESTION
ergotaminel moa
Answer:
,Thel primaryl mechanisml ofl actionl ofl ergotaminel inl thel treatmentl ofl migrainel isl notl
fullyl understood.l Ergotaminel canl alterl transmissionl atl serotonergic,l dopaminergic,l andl
alpha-adrenergicl junctions.l Currentl evidencel revealsl thatl antimigrainel effectsl couldl bel
relatedl tol agonistl activityl atl serotoninl receptors.l Inl craniall arteries,l ergotaminel actsl
directlyl tol promotel constrictionl andl reducel thel amplitudel ofl pulsations.
QUESTION
ergotaminel indication/use
Answer:
Ergotl alkaloidsl arel second-linel agentsl tol abortl activel migrainesl inl clientsl notl responsivel
tol triptans.
Usedl duringl activel migrainesl whenl clientsl arel unresponsivel tol first-linel treatment.
Canl leadl tol ergotism.
QUESTION
ergotl alkaloidl sidel effects
Answer:
QUESTION
ergotl alkaloidl blackl boxl warning
Answer:
canl causel intensel vasospasml andl subsequentl cerebrall orl peripherall ischemia.
QUESTION
ergotl alkaloidl dosing
Answer:
Sublinguall formulationsl arel administeredl asl onel tabletl (2l mg)l underl thel tonguel atl
migrainel onset.l Itl mayl bel repeatedl withl onel additionall tabletl atl 30-minutel intervalsl
twice.
, Ergotaminel andl caffeinel arel dosedl atl onel tol twol tabletsl (1mg/100l mg)l atl migrainel
onset.l Onel tabletl mayl bel repeatedl atl 30-minutel intervalsl fourl morel times.
Suppositoryl formulationsl (ergotaminel tartrate)l arel dosedl atl 2l mg/100l mg,l withl onel
suppositoryl PRl atl migrainel onsetl andl repeatedl inl onel hourl ifl needed.
Dihydroergotaminel intranasall sprayl isl dosedl atl onel sprayl (0.5l mg)l inl eachl nostrill atl
migrainel onset.l Itl mayl bel repeatedl inl 15l minutes.
QUESTION
ergotaminel teaching
Answer:
Clientsl shouldl bel counseledl onl thel riskl ofl ergotism,l symptomsl tol monitor,l andl thel
needl tol seekl medicall attentionl immediatelyl ifl warningl signsl orl symptomsl develop.
QUESTION
telll mel aboutl Serotoninl 1B/1Dl Receptorl Agonistsl (sumatriptanl [Imitrex])
Answer:
First-linel treatmentl forl activel migraines.
Directlyl stimulatesl serotoninl receptors.
Availablel inl injectable,l intranasal,l andl orall forms.l Canl causel coronaryl vasospasm.
Canl causel chestl symptomsl andl heavyl arms.
QUESTION
canl youl usel sumatriptanl orl ergotaminel inl pregnancy?
Answer:
Sumatriptanl wasl previouslyl classifiedl asl al Pregnancyl Riskl Categoryl Cl agent.l Itl shouldl
bel avoidedl inl pregnancyl unlessl necessary.
Ergotaminel wasl previouslyl classifiedl asl al Pregnancyl Riskl Categoryl Xl agent.l Itsl usel inl
pregnancyl isl contraindicatedl andl relatedl tol thel promotionl ofl uterinel contractions.
QUESTION
treatmentl forl mildl migraines
